Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Designing early detection programs for ovarian cancer.

Urban N.

Ann Oncol. 2011 Dec;22 Suppl 8:viii6-viii18. doi: 10.1093/annonc/mdr472.

2.

Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women.

Karlan BY, Thorpe J, Watabayashi K, Drescher CW, Palomares M, Daly MB, Paley P, Hillard P, Andersen MR, Anderson G, Drapkin R, Urban N.

Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1383-93. doi: 10.1158/1055-9965.EPI-13-1361. Epub 2014 May 1.

3.

HE4 as an Early Detection Biomarker of Epithelial Ovarian Cancer: Investigations in Prediagnostic Specimens From the Janus Serumbank.

Gislefoss RE, Langseth H, Bolstad N, Nustad K, Mørkrid L.

Int J Gynecol Cancer. 2015 Nov;25(9):1608-15. doi: 10.1097/IGC.0000000000000532.

PMID:
26501436
4.

The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.

Lenhard M, Stieber P, Hertlein L, Kirschenhofer A, Fürst S, Mayr D, Nagel D, Hofmann K, Krocker K, Burges A.

Clin Chem Lab Med. 2011 Sep 16;49(12):2081-8. doi: 10.1515/CCLM.2011.709.

PMID:
21923475
5.

Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.

Bandiera E, Zanotti L, Fabricio AS, Bucca E, Squarcina E, Romani C, Tassi R, Bignotti E, Todeschini P, Tognon G, Romagnolo C, Gion M, Sartori E, Maggino T, Pecorelli S, Ravaggi A.

Clin Chem Lab Med. 2013 Sep;51(9):1815-24. doi: 10.1515/cclm-2013-0151.

PMID:
24013103
6.

Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.

Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD, Urban N, Drescher CW.

Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1365-72. doi: 10.1158/1055-9965.EPI-08-1034.

7.

Potential role of HE4 in multimodal screening for epithelial ovarian cancer.

Urban N, Thorpe JD, Bergan LA, Forrest RM, Kampani AV, Scholler N, O'Briant KC, Anderson GL, Cramer DW, Berg CD, McIntosh MW, Hartge P, Drescher CW.

J Natl Cancer Inst. 2011 Nov 2;103(21):1630-4. doi: 10.1093/jnci/djr359. Epub 2011 Sep 14.

8.

Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule.

Drescher CW, Shah C, Thorpe J, O'Briant K, Anderson GL, Berg CD, Urban N, McIntosh MW.

J Clin Oncol. 2013 Jan 20;31(3):387-92. doi: 10.1200/JCO.2012.43.6691. Epub 2012 Dec 17.

9.

HE4--a novel promising serum marker in the diagnosis of ovarian carcinoma.

Langmár Z, Németh M, Vleskó G, Király M, Hornyák L, Bösze P.

Eur J Gynaecol Oncol. 2011;32(6):605-10. Review.

PMID:
22335019
10.

A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer.

Stiekema A, Lok CA, Kenter GG, van Driel WJ, Vincent AD, Korse CM.

Gynecol Oncol. 2014 Mar;132(3):573-7. doi: 10.1016/j.ygyno.2014.01.005. Epub 2014 Jan 10.

PMID:
24418200
11.

A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care.

Shadfan BH, Simmons AR, Simmons GW, Ho A, Wong J, Lu KH, Bast RC Jr, McDevitt JT.

Cancer Prev Res (Phila). 2015 Jan;8(1):37-48. doi: 10.1158/1940-6207.CAPR-14-0248. Epub 2014 Nov 11.

12.

Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.

Kristjansdottir B, Levan K, Partheen K, Sundfeldt K.

Gynecol Oncol. 2013 Oct;131(1):52-8. doi: 10.1016/j.ygyno.2013.07.094. Epub 2013 Jul 25.

13.

Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer.

Tcherkassova J, Abramovich C, Moro R, Chen C, Schmit R, Gerber A, Moro R.

Tumour Biol. 2011 Aug;32(4):831-8. doi: 10.1007/s13277-011-0186-1. Epub 2011 May 28.

14.

Significance of adding progesterone to the Risk of Ovarian Malignancy Algorithm for early stage ovarian cancer detection in patients with a pelvic mass: A single-center case-control study.

Pitynski K, Sporek A, Lipinska I, Banas T, Ludwin A, Bałajewicz-Nowak M.

Taiwan J Obstet Gynecol. 2015 Dec;54(6):766-72. doi: 10.1016/j.tjog.2015.10.006.

15.

Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.

Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV.

Gynecol Oncol. 2012 Nov;127(2):379-83. doi: 10.1016/j.ygyno.2012.07.106. Epub 2012 Jul 24.

PMID:
22835718
16.

[Serum tumor markers CA125 and HE4 in ovarian cancer patients].

Sergeeva NS, Marshutina NV, Alentov II, Korneeva IA, Novikova EG.

Vopr Onkol. 2013;59(2):12-21. Review. Russian. No abstract available.

PMID:
23814844
17.

Combined detection of sialic acid and hydroxyproline in diagnosis of ovarian cancer and its comparison with human epididymis protein 4 and carbohydrate antigen 125.

Li PL, Zhang X, Li TF, Wang LL, Du LT, Yang YM, Li J, Wang HY, Zhang Y, Wang CX.

Clin Chim Acta. 2015 Jan 15;439:148-53. doi: 10.1016/j.cca.2014.10.026. Epub 2014 Oct 27.

PMID:
25445414
18.

Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.

Menon U, Talaat A, Rosenthal AN, Macdonald ND, Jeyerajah AR, Skates SJ, Sibley K, Oram DH, Jacobs IJ.

BJOG. 2014 Dec;121 Suppl 7:35-9. doi: 10.1111/1471-0528.13211.

19.

A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.

Russell MR, Graham C, D'Amato A, Gentry-Maharaj A, Ryan A, Kalsi JK, Ainley C, Whetton AD, Menon U, Jacobs I, Graham RLJ.

Br J Cancer. 2017 Aug 22;117(5):666-674. doi: 10.1038/bjc.2017.199. Epub 2017 Jun 29.

20.

Usefulness of the HE4 biomarker as a second-line test in the assessment of suspicious ovarian tumors.

Moszynski R, Szubert S, Szpurek D, Michalak S, Krygowska J, Sajdak S.

Arch Gynecol Obstet. 2013 Dec;288(6):1377-83. doi: 10.1007/s00404-013-2901-1. Epub 2013 May 31.

Supplemental Content

Support Center